Loading
Life sciences · Journal article
Biology and Medical Engineering · September 18, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
This study explores the reversal effect of targeting mitochondrial metabolic reprogramming on CD8⁺ T cell exhaustion within the tumor microenvironment and its synergistic mechanism when combined with immune checkpoint blockade therapy. B16-OVA melanoma and LLC lung cancer tumor-bearing mouse models were established. Using single-cell RNA sequencing, metabolic flux analysis, Seahorse cellular energy metabolism assay, and flow cytometry, we compared the mitochondrial function, metabolic characteristics, and exhaustion phenotypes of tumor-infiltrating CD8⁺ T cells with CD8⁺ T cells from the spleen/draining lymph nodes. By pharmacologically activating or overexpressing genes to intervene in the PGC-1α-mediated mitochondrial biogenesis pathway, we evaluated CD8⁺ T cell mitochondrial membrane potential, ROS levels, ATP production, oxygen consumption rate, and the ability to secrete IFN-γ, TNF-α, and Granzyme B. Further, combined treatment with anti-PD-1 was applied to observe tumor growth, survival, and the composition of tumor-infiltrating lymphocytes. Tumor-infiltrating CD8⁺ T cells exhibited reduced mitochondrial membrane potential, accumulated ROS, decreased oxygen consumption rate and ATP production, and showed increased expression of PD-1, TIM-3, LAG-3, and TOX, suggesting that metabolic dysfunction is closely related to T cell exhaustion. Targeting mitochondrial metabolic reprogramming can restore mitochondrial adaptability of CD8⁺ T cells, enhance their proliferation, cytokine secretion, and cytotoxicity, while reducing expression of exhaustion-associated molecules. The combination of this intervention with anti-PD-1 antibody significantly inhibited tumor growth, extended survival in tumor-bearing mice, and increased the proportion of stem-like/effector memory CD8⁺ T cells in tumors. Mitochondrial metabolic reprogramming is a key regulatory node for reversing CD8⁺ T cell exhaustion. Targeting this pathway can remodel the tumor immune microenvironment and enhance the response to immune checkpoint therapy, providing a potential new strategy for cancer immunotherapy.